Navigation Links
Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
Date:2/6/2009

SAN DIEGO, Feb. 6 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today announced that it will report is operating results for the fourth quarter and all of fiscal 2008 on Tuesday, February 17.

The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Standard Time (5 p.m., Eastern Standard Time), Tuesday, February 17, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer.

The teleconference can be accessed by calling (719) 325-4758, passcode 8404715, Please dial in 10-15 minutes prior to the beginning of the call. The webcast will be available through the company's website at http://www.volcanocorp.com.

A replay of the conference call will be available through Tuesday, February 24, at (719) 457-0820, passcode 8404715, and via the company's website.

About Volcano Corporation

Volcano Corporation (NASDAQ: VOLC) offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart disease and guide optimal therapies. The company's intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into virtually any modern cath lab. Volcano IVUS offers unique features, including both single-use phased array and rotational IVUS imaging catheters, and advanced functionality options, such as VH(R) IVUS tissue characterization and Chr
'/>"/>

SOURCE Volcano Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Volcano Corporation Announces Proposed Public Offering of Common Stock
2. Volcano Corporation Reports Preliminary Third Quarter 2007 Revenues
3. Volcano Reports Record Third Quarter Revenues
4. Volcano Corporation Presentation at Piper Jaffray Conference to be Webcast
5. Volcano Corporation Selects Xactly to Drive Strategic Sales Performance Management
6. Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent
7. Chilean volcano captured blasting ash
8. Volcano Corporation Presentation at JMP Conference to be Webcast
9. Volcano Presentation at Canaccord Adams Conference to be Webcast
10. Volcano Corporation Announces the Relocation of Corporate Headquarters to San Diego
11. Volcano Reports 40 Percent Growth in Quarterly Revenues

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...device control capabilities will enable system cen...nhance their data security policy enforcement. , .... 9, 2009 -- Lumension, a global leader in endpoin...eral availability of Lumension® Device Contro...ers to protect corporate data while reducing opera...
(Date:11/9/2009)...rporation announces that their design, production ... Minneapolis, MN (Vocus) November 9, 2... manufacturer of miniature high-rel connectors, an...ms have been certified to the ISO 9001:2000 (w/des...stem Standard., , ,The company,s entire quality sy...
(Date:11/9/2009)... under increasing pressure to play only one sport ... System study of 519 junior tennis players has fou...injury. Researchers who analyzed 3,366 matches in ...n found that players who specialized in only tenni...r medical reasons, typically injuries. , Also, p...
(Date:11/8/2009)...dicare, improve coverage for all Americans ,, ...RY: Yesterday the United States House of Represen...tion that would strengthen Medicare for seniors an...rices millions of Americans out of affordable heal...r America Act (H.R. 3962) makes prescription drugs...
(Date:11/8/2009)...later, doctors say , , SUNDAY, Nov. 8 (H...e NFL this season, sidelining such stars as quarte..., Officials at the American Podiatric Medical A...s Medicine are warning athletes to take care of th...and lacrosse. , "Many fall sports athletes look...
Breaking Medicine News(10 mins):Health News:Lumension Announces General Availability of its Data Protection Solution for Microsoft System Center and Joins Microsoft System Center Alliance 2Health News:Lumension Announces General Availability of its Data Protection Solution for Microsoft System Center and Joins Microsoft System Center Alliance 3Health News:Lumension Announces General Availability of its Data Protection Solution for Microsoft System Center and Joins Microsoft System Center Alliance 4Health News:Omnetics Connector Corporation Achieves AS9100 Certification 2Health News:Young tennis players who play only 1 sport are more prone to injuries 2Health News:AARP NY Praises House Passage of Health Care Reform Bill 2Health News:AARP NY Praises House Passage of Health Care Reform Bill 3Health News:AARP NY Praises House Passage of Health Care Reform Bill 4Health News:Rx for Fall Foot Injuries 2
... University of Georgia have conducted a new study ... in the body react to parasitic diseases that affe...ed by scientists at the University of Georgia, tha...ce, states that scientists now have a better under...
...g Parkinson’s patient has challenged the view of T...medical emergency care alarm service, which the// ...inant, Mrs. C, has not minced words that the rulin...ergency care system in her home in 2002. This allo...
...ose brain damage at birth has turned him into a vi...the doctors his parents hold guilty, but that is o... Dispute Redressal (NCDR) forum has ordered the Co...medical negligence. The money was given away last ...
...n and radio ad campaign blaming GOP lawmakers for ...tion drug program has been launched by the// Assoc... The ad campaign accusing the lawmakers for bloc...ican House members from Pennsylvania, Indiana, New...
...00 operations were cancelled by 34 hospitals acros...ing to the report from these hospitals thousands o...the hospitals they were scheduled to be admitted t... these some 3,598 were said to have been cancelled...
...pital has been given a clear idea about the expect...patients in the midst of psychiatric treatments. W...aiting times for patients, Lewis McDonald the depu...State Hospital ensures public safety by providing ...
Other Medicine News:Health News:An All Important Breakthrough Reached In Understanding T cell response For Parasitic Diseases 2Health News:An All Important Breakthrough Reached In Understanding T cell response For Parasitic Diseases 3Health News:Brain Defect boy Compensated for Medical Error 2Health News:Brain Defect boy Compensated for Medical Error 3Health News:Ad Campaign Targeting Republicans On Medicare Prescription Drug Program 2Health News:Cancellations of Operations touch 22,000 2
(Date:11/6/2009)...N, Mass., Nov. 6 DUSA Ph...ermatology company that is developing and marketin...ther products focused on patients with common skin...nd Chief Executive Officer, will present a corpora...ummit 2009 on Tuesday, November 10, 2009 at 10:00 ...
(Date:11/6/2009)...Calif., Nov. 6 Kaiser Foundation H...P/H), and their subsidiaries reported today a comb...the quarter ended September 30, 2009, compared to ...perating income in the third quarter was $336 mill... of last year. Net non-operating income was $233 m...
(Date:11/6/2009)...Nov. 6 Caraco Pharmaceut...nched ketorolac tromethamine ophthalmic solution, ...nd Drug Administration (FDA) for Sun Pharma,s Abbr...ular® ophthalmic solution on the first day fo...lac is therapeutically equivalent to Acular® ...
Breaking Medicine Technology:Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 2Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 3Kaiser Foundation Health Plan and Hospitals Report Third Quarter 2009 Financial Results 4Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution 2Cellular Dynamics International and VivoMedica Launch the CARDIOTOX Consortium to Validate a Human Cardiac Model for Preclinical Cardiotoxicity Testin 4994 1Cellular Dynamics International and VivoMedica Launch the CARDIOTOX Consortium to Validate a Human Cardiac Model for Preclinical Cardiotoxicity Testin 4994 2Cellular Dynamics International and VivoMedica Launch the CARDIOTOX Consortium to Validate a Human Cardiac Model for Preclinical Cardiotoxicity Testin 4994 3Cellular Dynamics International and VivoMedica Launch the CARDIOTOX Consortium to Validate a Human Cardiac Model for Preclinical Cardiotoxicity Testin 4994 4Transave Announces Positive Phase II Results For Once Daily ARIKACE 28TM 29 in the Treatment of Non CF Bronchiectasis Patients Who Have Pseudomonas Lu 4992 1Transave Announces Positive Phase II Results For Once Daily ARIKACE 28TM 29 in the Treatment of Non CF Bronchiectasis Patients Who Have Pseudomonas Lu 4992 2Transave Announces Positive Phase II Results For Once Daily ARIKACE 28TM 29 in the Treatment of Non CF Bronchiectasis Patients Who Have Pseudomonas Lu 4992 3Transave Announces Positive Phase II Results For Once Daily ARIKACE 28TM 29 in the Treatment of Non CF Bronchiectasis Patients Who Have Pseudomonas Lu 4992 4Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 1Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 2Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 3Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 4Schering Plough Reports Long Term Vicriviroc Data From Phase II Open Label Extension Study in Treatment Experienced HIV Infected Patients 4990 5
...nc., a,biopharmaceutical company engaged in the di... treatment of immune-mediated diseases, announced ...modified version of TRX1,MTRX1011A, an anti-CD4 mo...hat has begun enrolling patients. The clinical tri...th single and multiple doses of MTRX1011A.,Under t...
...ffectiveness of Autologous Therapy, DUSSELDORF, G...entative study of knee osteoarthritis, published i...itis and Cartilage", confirm,the safety and effect...matory proteins obtained from the patient,s own bl...rchers at Heinrich Heine University in Dusseldorf ...
Other Medicine Technology:Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 2Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 3Orthokine Treatment is Effective for Knee Arthritis, Even After Two Years 2
Snap-In Snap-Out®-II Strong Grasping Forceps Insert
Maryland Dissector, dual-incision
Optima III 45 Noninsulated Maryland Dissector
Palpation Probe, dual-incision
Medicine Products: